TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›CABA›Financials
Annual statements · SEC XBRL · FY2018 – FY2025

Cabaletta Bio, Inc. (CABA) financials

Income statement

Cabaletta Bio, Inc. (CABA) income statement, annual, from SEC filings
Fiscal yearFY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating income-$6.19M-$18.7M-$33.8M-$46.3M-$54.1M-$74.7M-$125M-$172M
Net income-$12.2M-$16.9M-$33.3M-$46.3M-$53.0M-$67.7M-$116M-$168M
EPS (diluted)-$6.87-$4.07-$1.44-$1.80-$1.81-$1.65-$2.34-$2.10

Cash flow

Cabaletta Bio, Inc. (CABA) cash flow, annual, from SEC filings
Fiscal yearFY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$4.66M-$16.0M-$26.8M-$34.1M-$46.4M-$53.5M-$88.2M-$131M
Capital expenditures—$693K$635K$1.17M$2.45M$687K$2.21M$1.23M
Free cash flow—-$16.7M-$27.4M-$35.3M-$48.8M-$54.2M-$90.4M-$132M

Balance sheet

Cabaletta Bio, Inc. (CABA) balance sheet, annual, from SEC filings
Fiscal yearFY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$33.0M$136M$101M$122M$81.6M$193M$164M$83.0M
Total assets$34.2M$141M$115M$126M$117M$254M$185M$165M
Total liabilities———$8.38M$12.4M$17.5M$32.7M$53.0M
Shareholders' equity-$10.7M$138M$110M$118M$105M$236M$152M$112M
Retained earnings-$12.5M-$33.0M-$66.3M-$113M-$166M-$233M-$349M-$517M
Shares (wtd avg diluted)3.85M24.0M24.1M28.9M29.4M47.8M50.7M100M

Every figure is extracted from Cabaletta Bio, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Cabaletta Bio, Inc.'s free cash flow?
-$132M in FY2025 (operating cash flow -$131M minus $1.23M of capital expenditures), from the SEC cash-flow statement.
Does CABA pay a dividend?
Cabaletta Bio, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full CABA analysis — verdict, score & filings →Is CABA a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.